Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Infectious Disease In Vitro Diagnostics Market Set To Climb From $16.13 Billion In 2026 To $21.25 Billion By 2030
The infectious disease in vitro diagnostics market has shown robust growth over recent years. Its size is expected to increase from $15.1 billion in 2025 to $16.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The observed growth in previous periods can be linked to the worldwide prevalence of infectious diseases, the expansion of hospital laboratory capabilities, the imperative for timely diagnosis, advancements in immunoassay technologies, and government-led programs for disease control.
The infectious disease in vitro diagnostics market is projected to demonstrate significant expansion in the coming years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period can be attributed to initiatives for pandemic preparedness, an increase in molecular diagnostics, the rising issue of antimicrobial resistance, the expansion of diagnostic laboratories, and increased healthcare screening efforts. Major trends anticipated within the forecast period include the rapid adoption of molecular diagnostics, point-of-care infectious disease testing, highly sensitive pathogen detection methods, the implementation of multiplex diagnostic panels, and enhanced surveillance testing.
Get A Free Sample Report With In-Depth Market Insights:
Infectious Disease In Vitro Diagnostics Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing global prevalence of infectious diseases spurred the expansion of the infectious disease in vitro diagnostics market during the historic period. Infectious diseases pertain to individuals worldwide affected by bacterial, viral, fungal, or parasitic infections at a specific moment, signifying the overall disease burden within populations. Climate change has expanded the habitats of disease-carrying vectors, such as mosquitoes, leading to an increase in the global prevalence of infectious diseases. The infectious disease in vitro diagnostics support this trend by supplying precise and timely diagnostic tools that enable healthcare providers to identify pathogens, initiate appropriate treatment, and contain outbreaks more effectively. For instance, in October 2024, according to the World Health Organization, a Switzerland-based health authority, approximately 10.8 million people worldwide contracted tuberculosis, with 55% being men, 33% women, and 12% children and adolescents, and individuals living with human immunodeficiency virus (HIV) representing 6.1% of cases. Therefore, the growing global prevalence of infectious diseases fueled the growth of the infectious disease in vitro diagnostics market during the historic period.
Infectious Disease In Vitro Diagnostics Market Segmentation And Category Overview
The infectious disease in vitro diagnostics market covered in this report is segmented –
1) By Product Type: Instruments, Reagents, Software And Services
2) By Technology: Molecular Diagnostics, Immunoassay, Microbiology
3) By Application: Methicillin-Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile, Respiratory Virus, Tuberculosis (TB) And Drug-Resistant Tuberculosis (TB), Gonorrhea, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Hepatitis C, Hepatitis B, Other Applications
4) By End-Use: Hospitals And Clinics, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction Machines, Immunoassay Analyzers, Microbiology Analyzers, Next Generation Sequencers
2) By Reagent: Molecular Reagents, Immunoassay Reagents, Microbiology Reagents, Enzymes And Buffers, Controls And Calibrators
3) By Software And Services: Data Management Software, Laboratory Information Systems, Cloud Based Solutions, Maintenance And Support Services, Consulting And Training Services
#Infectious Disease In Vitro Diagnostics Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the infectious disease in vitro diagnostics market are concentrating on developing innovative products, such as the swift identification of numerous gastrointestinal pathogens, to enable timely diagnosis, enhance patient outcomes, and expand point-of-care testing capabilities. This rapid detection refers to diagnostic tests designed to quickly pinpoint the presence of multiple disease-causing microorganisms in the gastrointestinal tract from a single sample. For instance, in June 2024, MP Biomedicals, a US-based provider offering a diverse array of products, chemicals, and diagnostics, introduced a collection of immunochromatographic-based rapid diagnostic kits specifically for gastrointestinal infectious diseases. These kits facilitate quick and accurate detection of Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. Their features include rapid, point-of-care qualitative detection, versatile sample utilization (stool, blood, plasma, serum, water, and food), and suitability for both clinical and research applications. By leveraging cutting-edge immunochromatographic technology, these kits support early diagnosis, aid in monitoring treatment effectiveness, and confirm pathogen eradication, thereby representing a significant advancement in gastrointestinal health diagnostics through their combination of speed, precision, and broad pathogen coverage.
Infectious Disease In Vitro Diagnostics Market Leading Companies And Competitive Benchmarking
Major companies operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, bioMérieux SA, QIAGEN N.V., Becton Dickinson and Company, Hologic Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Revvity Inc., OraSure Technologies Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries Ltd., Bio-Rad Laboratories Inc., Trivitron Healthcare
View The Full Infectious Disease In Vitro Diagnostics Market Report:
Infectious Disease In Vitro Diagnostics Market Largest Region By Revenue And Market Share
North America was the largest region in the infectious disease in vitro diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model